Cellumed Co. Ltd
Cellumed Co.,Ltd., a biotechnology company, provides bone graft materials, medical devices, and cosmeceuticals in South Korea. The company offers CLnZyme, a mRNA enzyme; cosmeceuticals, such as FGF7 for skin regeneration and TGFß-1 for tissue regeneration; and electric motorcycles. It provides tissue bank products, such as celluderm powder, ultra, and HD implant for the skin; patellar tendon hemi… Read more
Cellumed Co. Ltd (049180) - Total Liabilities
Latest total liabilities as of September 2025: ₩55.10 Billion KRW
Based on the latest financial reports, Cellumed Co. Ltd (049180) has total liabilities worth ₩55.10 Billion KRW as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Cellumed Co. Ltd - Total Liabilities Trend (2008–2024)
This chart illustrates how Cellumed Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Cellumed Co. Ltd Competitors by Total Liabilities
The table below lists competitors of Cellumed Co. Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Shangri La Hotels Malaysia Bhd
KLSE:5517
|
Malaysia | RM405.20 Million |
|
Mutual-Tek Industries Co., Ltd.
TWO:6407
|
Taiwan | NT$1.56 Billion |
|
Ouro Fino Saúde Animal Participações S.A
SA:OFSA3
|
Brazil | R$747.37 Million |
|
Romerike Sparebank
OL:ROMER
|
Norway | Nkr16.57 Billion |
|
Careium AB
ST:CARE
|
Sweden | Skr407.40 Million |
|
District Metals Corp.
PINK:DMXCF
|
USA | $273.08K |
|
Marathon Bancorp, Inc. Common Stock
PINK:MBBC
|
USA | $201.13 Billion |
Liability Composition Analysis (2008–2024)
This chart breaks down Cellumed Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.05 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 3.38 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.77 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Cellumed Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Cellumed Co. Ltd (2008–2024)
The table below shows the annual total liabilities of Cellumed Co. Ltd from 2008 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩61.45 Billion | +41.41% |
| 2023-12-31 | ₩43.45 Billion | +10.54% |
| 2022-12-31 | ₩39.31 Billion | -18.75% |
| 2021-12-31 | ₩48.38 Billion | +13.31% |
| 2020-12-31 | ₩42.70 Billion | -28.59% |
| 2019-12-31 | ₩59.80 Billion | +125.12% |
| 2018-12-31 | ₩26.56 Billion | -4.11% |
| 2017-12-31 | ₩27.70 Billion | +19.24% |
| 2016-12-31 | ₩23.23 Billion | -42.97% |
| 2015-12-31 | ₩40.73 Billion | +54.34% |
| 2014-12-31 | ₩26.39 Billion | -7.64% |
| 2013-12-31 | ₩28.57 Billion | -15.55% |
| 2012-12-31 | ₩33.84 Billion | -28.76% |
| 2011-12-31 | ₩47.49 Billion | +238.53% |
| 2008-12-31 | ₩14.03 Billion | -- |